Navigation Links
Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
Date:9/17/2007

MELBOURNE, Australia, Sept. 17 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that, following successful preclinical studies, it plans to undertake a Phase 1 transdermal oxycodone clinical trial aimed at providing chronic pain sufferers with a sustained-release pain management product.

Phosphagenics has submitted all necessary documents for approval of the trial, which is to be conducted at CMAX - an independent clinical research organization located at the Royal Adelaide Hospital. The trial, which will be in up to 30 healthy volunteers, will evaluate the tolerability and safety of the novel transdermal oxycodone. The trial will begin once approval has been received, which is expected within the next six weeks.

The Company is working towards becoming the first to provide chronic pain sufferers with a patch that will provide sustained-release of oxycodone into the bloodstream. Previous clinical trials have demonstrated that Phosphagenics' patented technologies can effectively deliver opiates through the skin without causing any disruption or irritation.

Harry Rosen, Phosphagenics' President and CEO, said: "We have prioritized oxycodone over morphine in our pain management pipeline as we are in commercial discussions with several companies.

"These companies' commercial interests are focused on the license of a transdermal pain product containing oxycodone."

Dr. Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "Our objective is to address a large unmet need by using our technology to deliver oxycodone in a sustained-release formulation to treat pain beyond a 24 hour period."

Oxycodone, currently administered in tablet or intravenous form, in an eight to 12 hour formulation, is more potent than morphine with fewer adverse effects and its worldwide sales exceed $1 billion annually.

About Phosphagenics Limited

Phosphagenics is a
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
4. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...BURGH, Nov. 24 ,, WHAT: Rom H... for 23 years following an auto accident, was actu...d was the subject of a Good Morning America segmen... to illustrate how people with Locked-in Syndrome ..., WHEN: Good Morning America -- Tuesday, Novemb...
(Date:11/24/2009)...ISON, N.J., Nov. 24 Ques...ld,s leading provider of diagnostic testing, infor...d to speak at the 21st Annual Piper Jaffray Health...n is scheduled for Wednesday, December 2, 2009 at ...e, the company will reaffirm its 2009 guidance for...
(Date:11/24/2009)...EGO, Nov. 24 Anadys Phar... that it will present at the 21st Annual Piper Jaf... 2009 at 9:00 a.m. EST (6:00 a.m. PST). The confe... Steve Worland, Ph.D., President and Chief Executi...Anadys and its clinical development programs, ANA5...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Amgen Named Presenting Sponsor of The Dempsey Challenge 3A A Journey For Hope 56650 1Amgen Named Presenting Sponsor of The Dempsey Challenge 3A A Journey For Hope 56650 2Amgen Named Presenting Sponsor of The Dempsey Challenge 3A A Journey For Hope 56650 3Amgen Named Presenting Sponsor of The Dempsey Challenge 3A A Journey For Hope 56650 4Ancient oceans offer new insight into the origins of animal life 9852 1Ancient oceans offer new insight into the origins of animal life 9852 249th ICAAC press kit now available online 9848 1
... Response or Reduction of,Lesion Size by More than...RNewswire-FirstCall/ - Nventa,Biopharmaceuticals C...itive results from a clinical trial examining the ...estigational therapeutic,vaccine for human papillo...highest grade of cervical dysplasia (CIN III). The...
...7 - Accentia,Biopharmaceuticals, Inc. (NASDAQ: ABP...of the American Academy of Allergy, Asthma, and,Im... CA. The,posters discussed findings from a survey ...the U.S., U.K., France, and Germany on the,burden ...udes of,the fungal etiology of CS, and the differe...
Other Medicine Technology:Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 2Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 3Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 5
(Date:11/27/2009)...27 The Gymboree Corporat... CFO/COO, will present at the NASDAQ OMX 23rd Inve...otel in London, England, on Wednesday, December 2,...e broadcast of The Gymboree Corporation,s presenta...ree.com, click on "Our Company" at the bottom of t...
(Date:11/27/2009)...ission vehicles may reduce future disease burden, ...lthDay News) -- Encouraging city dwellers to walk ... greater public health benefits than increased use...found. , The study compared the projected healt...ort scenarios for London, England, and Delhi, Indi...
(Date:11/27/2009)...alist manufacturers who use medical load cells at ... dollars by bringing in technology partner Flintec...f pro-active medical manufacturers are calling in ...their projects, ensuring that progress will not be...tially outdated technology. , ...
(Date:11/26/2009)...tetrathiomolybdate (TM) has been shown in studies ..., a disease caused by an overload of copper, and c...y little, however, is known about how the drug wor...Northwestern University researchers now has provid...ture of TM bound to copper-loaded metallochaperone...
(Date:11/26/2009)...rch Triangle Dental (RTDental), a leading dental g...ounced the expansion of its services to include LU...Macmillan. , Durham, N...o announce that Dr. Doug Macmillan, an experienced...onal advanced training seminar. RTDental’s ...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
... Plan of Action on Behalf of their Client, Joel, ...Services, Inc. and its ...ry,s law firm announced,today that they have filed...pose the misconduct and wrongdoings of,Durham Coun...
...EP MEDICATIONS , Insomnia occurs when people ha...t is a common sleep compliant. While a brief case ...itement or other emotion, more than 20 million Ame...nd often debilitating condition, can lead to sever...
... January 23, 2008RNA interference (RNAi) represent...olecules to silence specific genes associated with...s describing the state-of-the-art and potential th...a peer-reviewed journal published by Mary Ann Lieb...
...23 University students in America,are turning to ...whelming,numbers to boost their focus, stay up lat...scribed for Attention Deficit Hyperactivity Disord...,coveted drugs are no longer illegal, mind-alterin...
...uccess at European Patent Hearing is Confirmed by ...NBURGH, Scotland, January 23 The European Patent,...(the ,131, patent) not,valid as granted. In a ruli...ncing the EPO ruling as a success, despite the,fac...
...ow to Fight Premature Birth in Ohio, COLUMBUS, Oh... rate of premature birth is up once again from 12....erm births were recorded for,2005 and over 20 lawm...non-partisan caucus to increase awareness of,the s...
Other Medicine News:Health News:The Willie Gary Law Firm Files $1 Billion Lawsuit Against Durham County LME, Wake County LME, Five County LME, Mecklenberg County LME and Value Options, Inc. for Negligent and Intentional Misconduct Against Mental Health Agency 2Health News:AASM statement on use of sleep medications 2Health News:AASM statement on use of sleep medications 3Health News:The RNA drug revolution -- a new approach to gene therapy 2Health News:Prescription 'Mind Meds' Pose Dangerous Threat to College Students 2Health News:Aircraft Medical: European Patent Hearing 2Health News:Ohio Prematurity Caucus Forming to Meet Challenge 2Health News:Ohio Prematurity Caucus Forming to Meet Challenge 3
8.00mm Open Trephine Handle
Retinal Forceps: Smooth 1.0mm Tips, Vertical Action
Gass Retinal Detachment Hook, Flattened 13mm Fenestrated
Schockett Double Ended Depressor w/Clip
Medicine Products: